HER2 overexpression and cancer targeting

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 115-124

  Wang, Shao Chun ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; COMPLEMENTARY DNA; CURCUMIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMID DNA; PROTEIN BAD; PROTEIN EIA; PROTEIN GRP94; PROTEIN P185; RAF PROTEIN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR PEA3; TRASTUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEVER; HUMAN; INJECTION PAIN; ONCOGENE NEU; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035165102     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28553     Document Type: Conference Paper

References (125)

1. Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation
2. Involvement of growth factor receptors in the mammalian UVC response
3. The neu oncogene encodes an epidermal growth factor receptor-related protein
4. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
5. Similarity of protein encoded by the human c-erbB- 2 gene to the epidermal growth factor receptor
6. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
7. An intramembrane modulator of the erbB 2 receptor tyrosine kinase that potentiates neuregulin signaling
8. c-neu density govern receptor interactions and tyrosine kinase activation
9. erbB4
10. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling
11. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
12. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
13. The erbB-3 gene product is a receptor for heregulin
14. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
15. Role of HER2 gene overexpression in breast carcinoma
16. Hyperexpression of mitogen-activated protein kinase in human breast cancer
17. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signaling
18. Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments: Evidence for a p185(neu)containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site
19. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
20. HER2/neu signal transduction in human breast and ovarian cancer
21. Oncogene-initiated aberrant signaling engendets the metastatic phenotype: Synergistic transcription factor interactions are targets for cancer therapy
22. Oncogenic neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks neumediated cellular transformation
23. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
24. Regulation of cell death protease caspase-9 by phosphorylation
25. NF-kappaB activation by tumor necrosis factor requites the Akt serine-threonine kinase
26. NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling
27. HER2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kB pathway
28. neu: A relationship between disruption of this regulation and transformation
29. neu
30. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in NIH 3T3 cells
31. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
32. Amplification of the proto-neu gene facilitates oncogenic activation by a single point mutation
33. Mitosisspecific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor
34. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
35. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
36. Prognostic importance of c-erbB-2 expression in breast cancer
37. Prognostic significance of HER2 oncoprotein expression in breast cancer: A 30 year follow-up
38. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer
39. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease
40. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer
41. neu) in human non-small cell carcinomas of the lung
42. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer
43. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue
44. Amplification, overexpression, and rearrangement of the c-erbB-2 proto-oncogene in primary human stomach carcinomas
45. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma
46. Combination of EGFR, HER2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
47. c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
48. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products
49. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities
50. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER2/neu gene expression but not with ras gene mutations
51. neu levels in HER2/neu transfected human lung cancer cells
52. Transformation mediated by the human HER2 gene independent of the epidermal growth factor receptor
53. Heregulin betal-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase
54. From HER2/neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
55. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/neu tyrosine kinase
56. Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
57. mdr-l renders breast cancer cells highly resistant to Taxol
58. The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
59. cdc2 kinase
60. Humanization of an anti-p185HER2 antibody for human cancer therapy
61. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
62. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
63. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity
64. Tyrosine kinase inhibitor emodin suppresses growth of HER2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel
65. Suppressed transformation and induced differentiation of HER2/neu-overexpressing breast cancer cells by emodin
66. neu
67. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum
68. Sensitization of HER2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin
69. Inhibitory effects of curcumin on tumor initiation by benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene
70. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells
71. Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12-O-tetradecanoylphorbol-13-acetate induced tumor promotion
72. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells
73. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin
74. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94)
75. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound
76. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers
77. Cloning and characterization of the mouse neu promoter
78. Regulation of HER2/neu gene expression
79. Identification and characterization of a novel enhancer for the rat neu promoter
80. Mechanisms of deregulated HER2/neu expression in breast cancer cell lines
81. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumor lines
82. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells
83. Differentiation-stimulated activity binds an ETS-like, essential regulatory element in the human promyelocytic defensin-1 promoter
84. A role for the ETS domain transcription factor PEA3 in myogenic differentiation
85. ERM, a PEA3 subfamily of Ets transcription factors, can cooperate with c-Jun
86. Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins
87. The ETS-domain: A new DNA-binding motif that recognizes a purinerich core DNA sequence
88. The ets multigene family is conserved throughout the Metazoa
89. Evolution of the ets gene family
90. A single etsrelated transcription factor, E1AF, confers invasive phenotype on human cancer cells
91. The Ets protein PEA3 suppresses HER2/neu overexpression and inhibits tumorigenesis
92. Expression of the PEA3 group of EST-related transcription factors in human breast cancer cells
93. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells
94. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
95. Differential transformation of primary human embryo retinal cells by adenovirus E1 El regions and combinations of E1A (+) ras
96. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
97. Complete transformation by adenovirus 2 requires both EIA proteins
98. Repressed expression of the HER2/c-erbB-2 proto-oncogene by the adenovirus E1A gene products
99. Transcriptional repression of the neu proto-oncogene by the adenovirus 5E1A gene products
100. Adenovirus type 5E1A gene products act as transformation suppressors of the neu oncogene
101. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER2/neu
102. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
103. Re-expression of neuencoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function activity of E1A
104. Adenovirus E1A-mediated negative control of genes activated during F9 differentiation
105. Adenovirus A1E represses protease gene expression and inhibits metastasis of human tumor cells
106. The E1A gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells
107. Antioncogenic effect of adenovirus E1A in human tumor cells
108. Adenovirus E1A-mediated tumor suppression by a c-erbB2/neu-independent mechanism
109. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo
110. Axl-Gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity
111. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins
112. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 EIA and accompanies apoptosis
113. Inhibition of nuclear factor-kappa B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis
114. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of 1kB kinases and nuclear factor kB activities
115. p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: Suppression by E1B 19K and Bcl-2 proteins
116. p53-dependent apoptosis suppresses tumor growth and progression in vivo
117. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms
118. Involvement of co-activator p300 in the transcriptional regulation of the HER2/neu gene
119. Potentiation of cationic liposomemediated gene delivery by polycations
120. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
121. HER2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model
122. The tumor suppression activity of E1A in HER2/neu-overexpressing breast cancer
123. Safety studies of the intraperitoneal injection of E1A-liposome complex in mice
124. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model
125. Targeting HER2/neu-overexpressing cancer cells with transcriptional repressor genes delivered by cationic liposome